Related content

Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension

By TRENKWALDER P.   DAHL K.   LEHTOVIRTA M.   MULDER H.  

Blood Pressure, Vol. 9, Iss. 1, 2000-05 ,pp. : 57-57

Informa Healthcare

Access to resources Recommend Favorite

The Importance of Integrated Risk Management When Treating Patients with Hypertension: Benefits of Angiotensin II Receptor Antagonist Therapy

By Ruilope Luis   Segura Julian  

Clinical and Experimental Hypertension, Vol. 30, Iss. 5, 2008-07 ,pp. : 397-414

Informa Healthcare

Access to resources Recommend Favorite

Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension

By STUMPE K. O.   HAWORTH D.   HÖGLUND C.   KERWIN L.   MARTIN A.   SIMON T.   MASSON C.   KASSLER-TAUB K.   OSBAKKEN M.  

Blood Pressure, Vol. 7, Iss. 1, 1998-04 ,pp. : 31-37

Informa Healthcare

Access to resources Recommend Favorite

Effects of the Angiotensin Receptor Blocker Candesartan on Arterial Stiffness and Markers of Extracellular Matrix Metabolism in Patients with Essential Hypertension

By Sasamura Hiroyuki   Kitamura Yudai   Nakamura Mari   Ryuzaki Munekazu   Saruta Takao  

Clinical and Experimental Hypertension, Vol. 28, Iss. 5, 2006-06 ,pp. : 511-520

Informa Healthcare

Access to resources Recommend Favorite

Combination of Angiotensin II Receptor Antagonist with Calcium Channel Blocker or Diuretic as Antihypertensive Therapy for Patients with Chronic Kidney Disease

By Ishimitsu Toshihiko   Ohno Eri   Nakano Nobuyuki   Furukata Satoshi   Akashiba Akira   Minami Junichi   Numabe Atsushi   Matsuoka Hiroaki  

Clinical and Experimental Hypertension, Vol. 33, Iss. 6, 2011-10 ,pp. : 366-372

Informa Healthcare

Access to resources Recommend Favorite